| “Default” generation of neonatal regulatory T cells G Wang, Y Miyahara, Z Guo, M Khattar, SM Stepkowski, W Chen The Journal of Immunology 185 (1), 71-78, 2010 | 150 | 2010 |
| A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models ES Lightcap, P Yu, S Grossman, K Song, M Khattar, K Xega, X He, ... Science translational medicine 13 (611), eaba7791, 2021 | 65 | 2021 |
| Expanding and converting regulatory T cells: a horizon for immunotherapy M Khattar, W Chen, SM Stepkowski Archivum immunologiae et therapiae experimentalis 57, 199-204, 2009 | 49 | 2009 |
| IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+ CD25+ regulatory T cell which jointly restrain CD4+ CD25− cell activation G Wang, M Khattar, Z Guo, Y Miyahara, SP Linkes, Z Sun, X He, ... Immunology letters 132 (1-2), 61-68, 2010 | 31 | 2010 |
| A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells Z Guo, M Khattar, PM Schroder, Y Miyahara, G Wang, X He, W Chen, ... The Journal of Immunology 190 (7), 3153-3162, 2013 | 30 | 2013 |
| Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts M Khattar, R Deng, BD Kahan, PM Schroder, T Phan, LP Rutzky, ... Transplantation 95 (7), 919-927, 2013 | 28 | 2013 |
| Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells Y Miyahara, M Khattar, PM Schroder, B Mierzejewska, R Deng, R Han, ... American Journal of Transplantation 12 (6), 1409-1418, 2012 | 25 | 2012 |
| Interleukin-21 is a critical regulator of CD4 and CD8 T cell survival during priming under Interleukin-2 deprivation conditions M Khattar, Y Miyahara, PM Schroder, A Xie, W Chen, SM Stepkowski PLoS One 9 (1), e85882, 2014 | 20 | 2014 |
| TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming M Khattar, K Song, S Grossman, K Xega, X He, N Idamakanti, D Huszar Cancer research 79 (13_Supplement), 3252-3252, 2019 | 17 | 2019 |
| Interleukin 21 (IL-21) regulates chronic allograft vasculopathy (CAV) in murine heart allograft rejection M Khattar, CE Baum, P Schroder, JD Breidenbach, ST Haller, W Chen, ... Plos one 14 (11), e0225624, 2019 | 9 | 2019 |
| IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4+ T cells Z Guo, G Wang, Y Miyahara, M Khattar, SP Linkes, C Wang, J Xia, Y Pan, ... Immunology letters 128 (2), 116-123, 2010 | 9 | 2010 |
| Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2 M Khattar, T Traore, K Horton, M Gallery, P Brauer, J Riceberg, N Bodyak, ... The Journal of Immunology 200 (1_Supplement), 122.29-122.29, 2018 | 8 | 2018 |
| Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice R Deng, M Khattar, A Xie, PM Schroder, X He, W Chen, SM Stepkowski Transplantation 97 (12), 1216-1224, 2014 | 7 | 2014 |
| Optimizing the use of regulatory T cells in allotransplantation: recent advances and future perspectives CE Baum, B Mierzejewska, PM Schroder, M Khattar, S Stepkowski Expert review of clinical immunology 9 (12), 1303-1314, 2013 | 7 | 2013 |
| Transient combination therapy targeting the immune synapse abrogates T cell responses and prolongs allograft survival in mice PM Schroder, M Khattar, R Deng, A Xie, W Chen, SM Stepkowski Plos one 8 (7), e69397, 2013 | 5 | 2013 |
| AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model EE Drouin, D Savitsky, AM Gonzalez, R Gombos, D Chand, J Waight, ... Cancer Research 77 (13_Supplement), 3654-3654, 2017 | 4 | 2017 |
| PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy PM Schroder, M Khattar, CE Baum, Y Miyahara, W Chen, R Vyas, ... Diabetologia 58, 1309-1318, 2015 | 4 | 2015 |
| 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo R Burga, M Khattar, S Lajoie, K Pedro, C Foley, AV Ocando, J Tremblay, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 3 | 2021 |
| Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with … C Passaro, B Koscso, S Smith, V Young, T Ross, B Primack, N Ly, ... J. Immunother. Cancer https://doi. org/10.1136/jitc-2022-sitc2022 369, 2022 | 2 | 2022 |
| Abstract lb-294: Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (MAB) in a syngeneic breast cancer model expressing human HER2 T Traore, M Khattar Cancer Research 78 (13_Supplement), LB-294-LB-294, 2018 | 2 | 2018 |
John C. CastleChief Data Scientist, Monte Rosa Therapeutics在 monterosatx.com 的电子邮件经过验证
